Skip to main content

MolecularMD to Provide qRT-PCR Patient Monitoring for CML Alliance

NEW YORK (GenomeWeb News) - MolecularMD said today it is providing qRT-PCR-based patient monitoring for the CML Alliance, a Novartis-run program that aims to improve outcomes for patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia.
The Novartis drug Gleevec, or imatinib, is a kinase inhibitor that targets the BCR-ABL protein to treat CML. In clinical studies, patients prescribed Gleevec who achieve major molecular response as measured by qRT-PCR have the best five-year prognosis for progression-free survival, MolecularMD said.
MolecularMD’s test monitors BCR-ABL oncogene expression by qRT-PCR.
“Results provided by our lab will enable patients and their healthcare providers to confidently optimize treatment of CML,” said MolecularMD’s scientific founder Brian Druker.
Genzyme Genetics is also offering PCR-based BCR-ABL monitoring as part of the CML Alliance.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.